000141118 001__ 141118
000141118 005__ 20240229105119.0
000141118 0247_ $$2doi$$a10.1093/jnci/djy161
000141118 0247_ $$2pmid$$apmid:30299508
000141118 0247_ $$2ISSN$$a0027-8874
000141118 0247_ $$2ISSN$$a0198-0157
000141118 0247_ $$2ISSN$$a1460-2105
000141118 0247_ $$2altmetric$$aaltmetric:49413194
000141118 037__ $$aDKFZ-2018-01652
000141118 041__ $$aeng
000141118 082__ $$a610
000141118 1001_ $$aBuffart, Laurien M$$b0
000141118 245__ $$aTargeting Exercise Interventions to Patients With Cancer in Need: An Individual Patient Data Meta-Analysis.
000141118 260__ $$aOxford$$bOxford Univ. Press$$c2018
000141118 3367_ $$2DRIVER$$aarticle
000141118 3367_ $$2DataCite$$aOutput Types/Journal article
000141118 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1550146836_26423
000141118 3367_ $$2BibTeX$$aARTICLE
000141118 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000141118 3367_ $$00$$2EndNote$$aJournal Article
000141118 520__ $$aExercise effects in cancer patients often appear modest, possibly because interventions rarely target patients most in need. This study investigated the moderator effects of baseline values on the exercise outcomes of fatigue, aerobic fitness, muscle strength, quality of life (QoL), and self-reported physical function (PF) in cancer patients during and post-treatment.Individual patient data from 34 randomized exercise trials (n = 4519) were pooled. Linear mixed-effect models were used to study moderator effects of baseline values on exercise intervention outcomes and to determine whether these moderator effects differed by intervention timing (during vs post-treatment). All statistical tests were two-sided.Moderator effects of baseline fatigue and PF were consistent across intervention timing, with greater effects in patients with worse fatigue (Pinteraction = .05) and worse PF (Pinteraction = .003). Moderator effects of baseline aerobic fitness, muscle strength, and QoL differed by intervention timing. During treatment, effects on aerobic fitness were greater for patients with better baseline aerobic fitness (Pinteraction = .002). Post-treatment, effects on upper (Pinteraction < .001) and lower (Pinteraction = .01) body muscle strength and QoL (Pinteraction < .001) were greater in patients with worse baseline values.Although exercise should be encouraged for most cancer patients during and post-treatments, targeting specific subgroups may be especially beneficial and cost effective. For fatigue and PF, interventions during and post-treatment should target patients with high fatigue and low PF. During treatment, patients experience benefit for muscle strength and QoL regardless of baseline values; however, only patients with low baseline values benefit post-treatment. For aerobic fitness, patients with low baseline values do not appear to benefit from exercise during treatment.
000141118 536__ $$0G:(DE-HGF)POF3-317$$a317 - Translational cancer research (POF3-317)$$cPOF3-317$$fPOF III$$x0
000141118 588__ $$aDataset connected to CrossRef, PubMed,
000141118 7001_ $$aSweegers, Maike G$$b1
000141118 7001_ $$aMay, Anne M$$b2
000141118 7001_ $$aChinapaw, Mai J$$b3
000141118 7001_ $$avan Vulpen, Jonna K$$b4
000141118 7001_ $$aNewton, Rob U$$b5
000141118 7001_ $$aGalvão, Daniel A$$b6
000141118 7001_ $$aAaronson, Neil K$$b7
000141118 7001_ $$aStuiver, Martijn M$$b8
000141118 7001_ $$aJacobsen, Paul B$$b9
000141118 7001_ $$aVerdonck-de Leeuw, Irma M$$b10
000141118 7001_ $$0P:(DE-He78)a0c2037d9054be26907a05ae520d5756$$aSteindorf, Karen$$b11$$udkfz
000141118 7001_ $$aIrwin, Melinda L$$b12
000141118 7001_ $$aHayes, Sandi$$b13
000141118 7001_ $$aGriffith, Kathleen A$$b14
000141118 7001_ $$aLucia, Alejandro$$b15
000141118 7001_ $$aHerrero-Roman, Fernando$$b16
000141118 7001_ $$aMesters, Ilse$$b17
000141118 7001_ $$avan Weert, Ellen$$b18
000141118 7001_ $$aKnoop, Hans$$b19
000141118 7001_ $$aGoedendorp, Martine M$$b20
000141118 7001_ $$aMutrie, Nanette$$b21
000141118 7001_ $$aDaley, Amanda J$$b22
000141118 7001_ $$aMcConnachie, Alex$$b23
000141118 7001_ $$aBohus, Martin$$b24
000141118 7001_ $$aThorsen, Lene$$b25
000141118 7001_ $$aSchulz, Karl-Heinz$$b26
000141118 7001_ $$aShort, Camille E$$b27
000141118 7001_ $$aJames, Erica L$$b28
000141118 7001_ $$aPlotnikoff, Ronald C$$b29
000141118 7001_ $$aArbane, Gill$$b30
000141118 7001_ $$aSchmidt, Martina E$$b31
000141118 7001_ $$aPotthoff, Karin$$b32
000141118 7001_ $$avan Beurden, Marc$$b33
000141118 7001_ $$aOldenburg, Hester S$$b34
000141118 7001_ $$aSonke, Gabe S$$b35
000141118 7001_ $$avan Harten, Wim H$$b36
000141118 7001_ $$aGarrod, Rachel$$b37
000141118 7001_ $$aSchmitz, Kathryn H$$b38
000141118 7001_ $$aWinters-Stone, Kerri M$$b39
000141118 7001_ $$aVelthuis, Miranda J$$b40
000141118 7001_ $$aTaaffe, Dennis R$$b41
000141118 7001_ $$avan Mechelen, Willem$$b42
000141118 7001_ $$aJosé Kersten, Marie$$b43
000141118 7001_ $$aNollet, Frans$$b44
000141118 7001_ $$aWenzel, Jennifer$$b45
000141118 7001_ $$aWiskemann, Joachim$$b46
000141118 7001_ $$aBrug, Johannes$$b47
000141118 7001_ $$aCourneya, Kerry S$$b48
000141118 773__ $$0PERI:(DE-600)1465951-7$$a10.1093/jnci/djy161$$n11$$p1190-1200$$tJournal of the National Cancer Institute$$v110$$x1460-2105$$y2018
000141118 909CO $$ooai:inrepo02.dkfz.de:141118$$pVDB
000141118 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a0c2037d9054be26907a05ae520d5756$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000141118 9131_ $$0G:(DE-HGF)POF3-317$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vTranslational cancer research$$x0
000141118 9141_ $$y2018
000141118 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000141118 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJNCI-J NATL CANCER I : 2017
000141118 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000141118 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000141118 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000141118 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central
000141118 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000141118 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000141118 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000141118 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000141118 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000141118 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000141118 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000141118 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000141118 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000141118 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bJNCI-J NATL CANCER I : 2017
000141118 9201_ $$0I:(DE-He78)G210-20160331$$kG210$$lBewegung, Präventionsforschung und Krebs$$x0
000141118 980__ $$ajournal
000141118 980__ $$aVDB
000141118 980__ $$aI:(DE-He78)G210-20160331
000141118 980__ $$aUNRESTRICTED